- Home
- AKTX vs CRIS Comparison
AKTX vs CRIS Comparison
Compare AKTX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- CRIS
- Stock Information
- Founded
- AKTX N/A
- CRIS 2000
- Country
- AKTX United States
- CRIS United States
- Employees
- AKTX N/A
- CRIS N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKTX Health Care
- CRIS Health Care
- Exchange
- AKTX Nasdaq
- CRIS Nasdaq
- Market Cap
- AKTX 35.7M
- CRIS 22.9M
- IPO Year
- AKTX N/A
- CRIS 2000
- Fundamental
- Price
- AKTX $0.76
- CRIS $1.71
- Analyst Decision
- AKTX Strong Buy
- CRIS Strong Buy
- Analyst Count
- AKTX 2
- CRIS 2
- Target Price
- AKTX $3.30
- CRIS $16.50
- AVG Volume (30 Days)
- AKTX 91.6K
- CRIS 74.8K
- Earning Date
- AKTX 08-13-2025
- CRIS 11-13-2025
- Dividend Yield
- AKTX N/A
- CRIS N/A
- EPS Growth
- AKTX N/A
- CRIS N/A
- EPS
- AKTX N/A
- CRIS N/A
- Revenue
- AKTX N/A
- CRIS $11,405,000.00
- Revenue This Year
- AKTX N/A
- CRIS $1.41
- Revenue Next Year
- AKTX N/A
- CRIS $7.46
- P/E Ratio
- AKTX N/A
- CRIS N/A
- Revenue Growth
- AKTX N/A
- CRIS 12.24
- 52 Week Low
- AKTX $0.57
- CRIS $1.02
- 52 Week High
- AKTX $3.85
- CRIS $6.44
- Technical
- Relative Strength Index (RSI)
- AKTX 37.47
- CRIS 48.53
- Support Level
- AKTX $0.75
- CRIS $1.63
- Resistance Level
- AKTX $0.89
- CRIS $1.95
- Average True Range (ATR)
- AKTX 0.07
- CRIS 0.15
- MACD
- AKTX 0.01
- CRIS 0.01
- Stochastic Oscillator
- AKTX 57.86
- CRIS 29.41
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.